Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells

Fig. 3

Treatment-mediated expression profiles of proteins relevant to birinapant/paclitaxel pharmacodynamic interactions. PANC-1 cells were exposed to vehicle, 10 nM PTX, 100 nM BRP, or combined BRP/PTX (100/10 nM) for up to 72 h. Treatment-mediated changes are compared to the vehicle controls for each time point. For proteins quantified using the IonStar proteomic workflow (ASPP2, BAX, ELYS, IRAK4 and VDAC1), the temporal profiles were clustered, as described in Methods, and the mean temporal cluster profiles are shown. For proteins quantified by western blot (BCL2, cIAP1, phospho-JNK, NF-κB and STAT), the expression is normalized to housekeeping proteins GAPDH or β-actin. Squares represent the treatment-mediated fold-change of a protein, whereas lines represent the fitting results from the protein interaction model. Blue: 100 nM BRP; red: 10 nM PTX; magenta: BRP/PTX (100/10 nM) combined. The protein interactions are noted at the bottom of each panel. ➔: activation; ―| inhibition

Back to article page